Proteomics biomarkers for non-small cell lung cancer

Journal of Pharmaceutical and Biomedical Analysis

Volumn 101, Issue , 2014, Pages 40-49

  Kisluk, Joanna ^a   Ciborowski, Michal ^a   Niemira, Magdalena ^a   Kretowski, Adam ^a   Niklinski, Jacek ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Lung cancer proteomics; Non small cell lung cancer; NSCLC proteomic biomarkers; Proteomic biomarkers

Indexed keywords

BIOLOGICAL MARKER; CYTOKERATIN; ERLOTINIB; GEFITINIB; PROTEOME; TUMOR MARKER;

BLOOD; CANCER PROGNOSIS; HUMAN; HUMAN TISSUE; INTERSTITIAL FLUID; MOLECULAR PATHOLOGY; MOLECULAR WEIGHT; MULTIPLE SCLEROSIS; NON SMALL CELL LUNG CANCER; PLEURA EFFUSION; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEOMICS; REVIEW; SALIVA; TISSUES; URINE; DIAGNOSTIC USE; LUNG NEOPLASMS; METABOLISM; PROCEDURES; PROGNOSIS;

CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; PROGNOSIS; PROTEOME; PROTEOMICS; TUMOR MARKERS, BIOLOGICAL;

EID: 84908571788     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2014.07.038     Document Type: Review

References (72)

1. Kikuchi T., Hassanein M., Amann J.M., Liu Q., Slebos R.J.C., Rahman S.M.J., Kaufman J.M., Zhang X., Hoeksema M.D., Harris B.K., Li M., Shyr Y., Gonzalez A.L., Zimmerman L.J., Liebler D.C., Massion P.P., Carbone D.P. In-depth proteomic analysis of non-small cell lung cancer to discover molecular targets and candidate biomarkers. Mol. Cell. Proteomics 2012, 11:916-932.
2. Massion P.P., Caprioli R.M. Proteomic strategies for the characterization and the early detection of lung cancer. J. Thorac. Oncol. 2006, 1:1027-1039.
3. Griffin T.J., Aebersold R. Advances in proteome analysis by mass spectrometry. J. Biol. Chem. 2001, 276:45497-45500.
4. Kalinina J., Peng J., Ritchie J.C., Van Meir E.G. Proteomics of gliomas: initial biomarker discovery and evolution of technology. Neuro-oncology 2011, 13:926-942.
5. Langley S.R., Dwyer J., Drozdov I., Yin X., Mayr M. Proteomics: from single molecules to biological pathways. Cardiovasc. Res. 2013, 97:612-622.
6. Lipman D.J., Pearson W.R. Rapid and sensitive protein similarity searches. Science 1985, 227:1435-1441.
7. Qian W.-J., Jacobs J.M., Liu T., Camp D.G., Smith R.D. Advances and challenges in liquid chromatography-mass spectrometry-based proteomics profiling for clinical applications. Mol. Cell. Proteomics 2006, 5:1727-1744.
8. Nanjappa V., Thomas J.K., Marimuthu A., Muthusamy B., Radhakrishnan A., Sharma R., Ahmad Khan A., Balakrishnan L., Sahasrabuddhe N.A., Kumar S., Jhaveri B.N., Sheth K.V., Kumar Khatana R., Shaw P.G., Srikanth S.M., Mathur P.P., Shankar S., Nagaraja D., Christopher R., Mathivanan S., Raju R., Sirdeshmukh R., Chatterjee A., Simpson R.J., Harsha H.C., Pandey A., Prasad T.S.K. Plasma proteome database as a resource for proteomics research: 2014 update. Nucleic Acids Res. 2014, 42:D959-D965.
9. Tu C., Rudnick P.A., Martinez M.Y., Cheek K.L., Stein S.E., Slebos R.J., Liebler D.C. Depletion of abundant plasma proteins and limitations of plasma proteomics. J. Proteome Res. 2010, 9:4982-4991.
10. Pieper R., Su Q., Gatlin C.L., Huang S.T., Anderson N.L., Steiner S. Multi-component immunoaffinity subtraction chromatography: an innovative step towards a comprehensive survey of the human plasma proteome. Proteomics 2003, 3:422-432.
11. Yadav A.K., Bhardwaj G., Basak T., Kumar D., Ahmad S., Priyadarshini R., Singh A.K., Dash D., Sengupta S. A systematic analysis of eluted fraction of plasma post immunoaffinity depletion: implications in biomarker discovery. PLOS One 2011, 6:e24442.
12. Yanagisawa K., Tomida S., Shimada Y., Yatabe Y., Mitsudomi T., Takahashi T. A 25-signal proteomic signature and outcome for patients with resected non-small-cell lung cancer. J. Natl. Cancer Inst. 2007, 99:858-867.
13. De Petris L., Pernemalm M., Elmberger G., Bergman P., Orre L., Lewensohn R., Lehtiö J. A novel method for sample preparation of fresh lung cancer tissue for proteomics analysis by tumor cell enrichment and removal of blood contaminants. Proteome Sci. 2010, 8:9.
14. Indovina P., Marcelli E., Pentimalli F., Tanganelli P., Tarro G., Giordano A. Mass spectrometry-based proteomics: the road to lung cancer biomarker discovery. Mass Spectrom. Rev. 2013, 32:129-142.
15. Omenn G.S., States D.J., Adamski M., Blackwell T.W., Menon R., Hermjakob H., Apweiler R., Haab B.B., Simpson R.J., Eddes J.S., Kapp E.A., Moritz R.L., Chan D.W., Rai A.J., Admon A., Aebersold R., Eng J., Hancock W.S., Hefta S.A., Meyer H., Paik Y.K., Yoo J.S., Ping P., Pounds J., Adkins J., Qian X., Wang R., Wasinger V., Wu C.Y., Zhao X., Zeng R., Archakov A., Tsugita A., Beer I., Pandey A., Pisano M., Andrews P., Tammen H., Speicher D.W., Hanash S.M. Overview of the HUPO Plasma Proteome Project: results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core dataset of 3020 proteins and a publicly available database. Proteomics 2005, 5:3226-3245.
16. de Roos B. Proteomic analysis of human plasma and blood cells in nutritional studies: development of biomarkers to aid disease prevention. Expert Rev. Proteomics 2008, 5:819-826.
17. Indovina P., Marcelli E., Maranta P., Tarro G. Lung cancer proteomics: recent advances in biomarker discovery. Int. J. Proteomics 2011, 2011:726869.
18. Tyan Y.C., Liao P.C. Proteomics analysis of serous fluids and effusions: pleural, pericardial, and peritoneal. Proteomics Clin. Appl. 2007, 1:834-844.
19. Rodríguez-Piñeiro A.M., Blanco-Prieto S., Sánchez-Otero N., Rodríguez-Berrocal F.J., de la Cadena M.P. On the identification of biomarkers for non-small cell lung cancer in serum and pleural effusion. J. Proteomics 2010, 73:1511-1522.
20. Ahmed F.E. Sample preparation and fractionation for proteome analysis and cancer biomarker discovery by mass spectrometry. J. Sep. Sci. 2009, 32:771-798.
21. Hoorn E.J., Pisitkun T., Zietse R., Gross P., Frokiaer J., Wang N.S., Gonzales P.A., Star R.A., Knepper M.A. Prospects for urinary proteomics: exosomes as a source of urinary biomarkers. Nephrology (Carlton) 2005, 10:283-290.
22. Li Y., Zhang Y., Qiu F., Qiu Z. Proteomic identification of exosomal LRG1: a potential urinary biomarker for detecting NSCLC. Electrophoresis 2011, 32:1976-1983.
23. Theodorescu D., Mischak H. Mass spectrometry-based proteomics in urine biomarker discovery. World J. Urol. 2007, 25:435-443.
24. Li S., Wang R., Zhang M., Wang L., Cheng S. Proteomic analysis of non-small cell lung cancer tissue interstitial fluids. World J. Surg. Oncol. 2013, 11:173.
25. Xiao H., Zhang L., Zhou H., Lee J.M., Garon E.B., Wong D.T. Proteomic analysis of human saliva from lung cancer patients using two-dimensional difference gel electrophoresis and mass spectrometry. Mol. Cell. Proteomics 2012, 11. M111.012112.
26. Dziadziuszko R., Hirsch F.R. Advances in genomic and proteomic studies of non-small cell lung cancer: clinical and translational research perspective. Clin. Lung Cancer 2008, 9:78-84.
27. Li L.S., Kim H., Rhee H., Kim S.H., Shin D.H., Chung K.Y., Park K.S., Paik Y.K., Chang J. Proteomic analysis distinguishes basaloid carcinoma as a distinct subtype of non-small cell lung carcinoma. Proteomics 2004, 4:3394-3400.
28. Zeng G.Q., Yi H., Zhang P.F., Li X.H., Hu R., Li M.Y., Li C., Qu J.Q., Deng X., Xiao Z.Q. The function and significance of SELENBP1 downregulation in human bronchial epithelial carcinogenic process. PLOS One 2013, 8:e71865.
29. Assinder S.J., Stanton J.A., Prasad P.D. Transgelin: an actin-binding protein and tumor suppressor. Int. J. Biochem. Cell Biol. 2009, 41:482-486.
30. Rho J.H., Roehrl M.H., Wang J.Y. Tissue proteomics reveals differential and compartment-specific expression of the homologs transgelin and transgelin-2 in lung adenocarcinoma and its stroma. J. Proteome Res. 2009, 8:5610-5618.
31. Schremmer B., Manevich Y., Feinstein S.I., Fisher A.B. Peroxiredoxins in the lung with emphasis on peroxiredoxin VI. Subcell. Biochem. 2007, 44:317-344.
32. Park Y.H., Kim S.U., Lee B.K., Kim H.S., Song I.S., Shin H.J., Han Y.H., Chang K.T., Kim J.M., Lee D.S., Kim Y.H., Choi C.M., Kim B.Y., Yu D.Y. Prx I suppresses K-ras-driven lung tumorigenesis by opposing redox-sensitive ERK/cyclin D1 pathway. Antioxid. Redox Signal. 2013, 19:482-496.
33. Park J.H., Kim Y.S., Lee H.L., Shim J.Y., Lee K.S., Oh Y.J., Shin S.S., Choi Y.H., Park K.J., Park R.W., Hwang S.C. Expression of peroxiredoxin and thioredoxin in human lung cancer and paired normal lung. Respirology 2006, 11:269-275.
34. Tan F., Jiang Y., Sun N., Chen Z., Lv Y., Shao K., Li N., Qiu B., Gao Y., Li B., Tan X., Zhou F., Wang Z., Ding D., Wang J., Sun J., Hang J., Shi S., Feng X., He F., He J. Identification of isocitrate dehydrogenase 1 as a potential diagnostic and prognostic biomarker for non-small cell lung cancer by proteomic analysis. Mol. Cell. Proteomics 2012, 11.
35. Yang F., Xiao Z.Q., Zhang X.Z., Li C., Zhang P.F., Li M.Y., Chen Y., Zhu G.Q., Sun Y., Liu Y.F., Chen Z.C. Identification of tumor antigens in human lung squamous carcinoma by serological proteome analysis. J. Proteome Res. 2007, 6:751-758.
36. Hoagland L.F., Campa M.J., Gottlin E.B., Herndon J.E., Patz E.F. Haptoglobin and post-translational glycan-modified derivatives as serum biomarkers for the diagnosis of non-small cell lung cancer. Cancer 2007, 110:2260-2268.
37. Ulivi P., Mercatali L., Casoni G.L., Scarpi E., Bucchi L., Silvestrini R., Sanna S., Monteverde M., Amadori D., Poletti V., Zoli W. Multiple marker detection in peripheral blood for NSCLC diagnosis. PLOS One 2013, 8:e57401.
38. Park J., Yang J.S., Jung G., Woo H.I., Park H.D., Kim J.W., Huh W., Ko J.W., Kim H., Cho J.Y., Lee S.Y. Subunit-specific mass spectrometry method identifies haptoglobin subunit alpha as a diagnostic marker in non-small cell lung cancer. J. Proteomics 2013, 94:302-310.
39. Kanoh Y., Abe T., Masuda N., Akahoshi T. Progression of non-small cell lung cancer: diagnostic and prognostic utility of matrix metalloproteinase-2, C-reactive protein and serum amyloid A. Oncol. Rep. 2013, 29:469-473.
40. Howard B.A., Wang M.Z., Campa M.J., Corro C., Fitzgerald M.C., Patz E.F. Identification and validation of a potential lung cancer serum biomarker detected by matrix-assisted laser desorption/ionization-time of flight spectra analysis. Proteomics 2003, 3:1720-1724.
41. Li J., Xie Z., Shi L., Zhao Z., Hou J., Chen X., Cui Z., Xue P., Cai T., Wu P., Guo S., Yang F. Purification, identification, and profiling of serum amyloid A proteins from sera of advanced-stage cancer patients. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2012, 889-890:3-9.
42. Sung H.J., Ahn J.M., Yoon Y.H., Rhim T.Y., Park C.S., Park J.Y., Lee S.Y., Kim J.W., Cho J.Y. Identification and validation of SAA as a potential lung cancer biomarker and its involvement in metastatic pathogenesis of lung cancer. J. Proteome Res. 2011, 10:1383-1395.
43. Garbacki N., Di Valentin E., Piette J., Cataldo D., Crahay C., Colige A. Matrix metalloproteinase 12 silencing: a therapeutic approach to treat pathological lung tissue remodeling?. Pulm. Pharmacol. Ther. 2009, 22:267-278.
44. Zhang L., Chen J., Ke Y., Mansel R.E., Jiang W.G. Expression of pigment epithelial derived factor is reduced in non-small cell lung cancer and is linked to clinical outcome. Int. J. Mol. Med. 2006, 17:937-944.
45. Ohri C.M., Shikotra A., Green R.H., Waller D.A., Bradding P. The tissue microlocalization and cellular expression of CD163, VEGF, HLA-DR, iNOS, and MRP 8/14 is correlated to clinical outcome in NSCLC. PLOS One 2011, 6:e21874.
46. Kawai H., Minamiya Y., Takahashi N. Prognostic impact of S100A9 overexpression in non-small cell lung cancer. Tumour Biol. 2011, 32:641-646.
47. Pernemalm M., De Petris L., Eriksson H., Brandén E., Koyi H., Kanter L., Lewensohn R., Lehtiö J. Use of narrow-range peptide IEF to improve detection of lung adenocarcinoma markers in plasma and pleural effusion. Proteomics 2009, 9:3414-3424.
48. Yang J., Ramnath N., Moysich K.B., Asch H.L., Swede H., Alrawi S.J., Huberman J., Geradts J., Brooks J.S., Tan D. Prognostic significance of MCM2, Ki-67 and gelsolin in non-small cell lung cancer. BMC Cancer 2006, 6:203.
49. Yang J., Tan D., Asch H.L., Swede H., Bepler G., Geradts J., Moysich K.B. Prognostic significance of gelsolin expression level and variability in non-small cell lung cancer. Lung Cancer 2004, 46:29-42.
50. Zhu W.Y., Hunag Y.Y., Liu X.G., He J.Y., Chen D.D., Zeng F., Zhou J.H., Zhang Y.K. Prognostic evaluation of CapG, gelsolin, P-gp, GSTP1, and Topo-II proteins in non-small cell lung cancer. Anat. Rec. (Hoboken) 2012, 295:208-214.
51. Seike M., Kondo T., Fujii K., Okano T., Yamada T., Matsuno Y., Gemma A., Kudoh S., Hirohashi S. Proteomic signatures for histological types of lung cancer. Proteomics 2005, 5:2939-2948.
52. NIH consensus conference Treatment of early-stage breast cancer. JAMA 1991, 265:391-395.
53. Emberley E.D., Murphy L.C., Watson P.H. S100 proteins and their influence on pro-survival pathways in cancer. Biochem. Cell Biol. 2004, 82:508-515.
54. Zhao Y., Zhang T., Wang Q. S100 calcium-binding protein A4 is a novel independent prognostic factor for the poor prognosis of gastric carcinomas. Oncol. Rep. 2013, 30:111-118.
55. Fan B., Zhang L.H., Jia Y.N., Zhong X.Y., Liu Y.Q., Cheng X.J., Wang X.H., Xing X.F., Hu Y., Li Y.A., Du H., Zhao W., Niu Z.J., Lu A.P., Li J.Y., Ji J.F. Presence of S100A9-positive inflammatory cells in cancer tissues correlates with an early stage cancer and a better prognosis in patients with gastric cancer. BMC Cancer 2012, 12:316.
56. Yang H., Zhao K., Yu Q., Wang X., Song Y., Li R. Evaluation of plasma and tissue S100A4 protein and mRNA levels as potential markers of metastasis and prognosis in clear cell renal cell carcinoma. J. Int. Med. Res. 2012, 40:475-485.
57. Huang L.Y., Xu Y., Cai G.X., Guan Z.Q., Sheng W.Q., Lu H.F., Xie L.Q., Lu H.J., Cai S.J. S100A4 overexpression underlies lymph node metastasis and poor prognosis in colorectal cancer. World J. Gastroenterol. 2011, 17:69-78.
58. Tian T., Hao J., Xu A., Luo C., Liu C., Huang L., Xiao X., He D. Determination of metastasis-associated proteins in non-small cell lung cancer by comparative proteomic analysis. Cancer Sci. 2007, 98:1265-1274.
59. Liu Y.F., Chen Y.H., Li M.Y., Zhang P.F., Peng F., Li G.Q., Xiao Z.Q., Chen Z.C. Quantitative proteomic analysis identifying three annexins as lymph node metastasis-related proteins in lung adenocarcinoma. Med. Oncol. 2012, 29:174-184.
60. Yao H., Zhang Z., Xiao Z., Chen Y., Li C., Zhang P., Li M., Liu Y., Guan Y., Yu Y., Chen Z. Identification of metastasis associated proteins in human lung squamous carcinoma using two-dimensional difference gel electrophoresis and laser capture microdissection. Lung Cancer 2009, 65:41-48.
61. Sun N., Chen Z., Tan F., Zhang B., Yao R., Zhou C., Li J., Gao Y., Liu Z., Tan X., Zhou F., He M.Y.F., Shao K., Li N., Qiu B., Sun J., Yu Y., Wang S., Zhao Y., Shi X., He J. Isocitrate dehydrogenase 1 is a novel plasma biomarker for the diagnosis of non-small cell lung cancer. Clin. Cancer Res. 2013, 19:5136-5145.
62. Ono A., Takahashi T., Mori K., Akamatsu H., Shukuya T., Taira T., Kenmotsu H., Naito T., Murakami H., Nakajima T., Endo M., Yamamoto N. Prognostic impact of serum CYFRA 21-1 in patients with advanced lung adenocarcinoma: a retrospective study. BMC Cancer 2013, 13:354.
63. Park S.Y., Lee J.G., Kim J., Park Y., Lee S.K., Bae M.K., Lee C.Y., Kim D.J., Chung K.Y. Preoperative serum CYFRA 21-1 level as a prognostic factor in surgically treated adenocarcinoma of lung. Lung Cancer 2013, 79:156-160.
64. De Petris L., Brandén E., Herrmann R., Sanchez B.C., Koyi H., Linderholm B., Lewensohn R., Linder S., Lehtiö J. Diagnostic and prognostic role of plasma levels of two forms of cytokeratin 18 in patients with non-small cell lung cancer. Eur. J. Cancer 2011, 47:131-137.
65. Maeda J., Hirano T., Ogiwara A., Akimoto S., Kawakami T., Fukui Y., Oka T., Gong Y., Guo R., Inada H., Nawa K., Kojika M., Suga Y., Ohira T., Mukai K., Kato H. Proteomic analysis of stage I primary lung adenocarcinoma aimed at individualization of postoperative therapy. Br. J. Cancer 2008, 98:596-603.
66. Xu B.J., Gonzalez A.L., Kikuchi T., Yanagisawa K., Massion P.P., Wu H., Mason S.E., Olson S.J., Shyr Y., Carbone D.P., Caprioli R.M. MALDI-MS-derived prognostic protein markers for resected non-small cell lung cancer. Proteomics Clin. Appl. 2008, 2:1508-1517.
67. Molina-Pinelo S., Pastor M.D., Paz-Ares L. VeriStrat: a prognostic and/or predictive biomarker for advanced lung cancer patients?. Expert Rev. Respir. Med. 2014, 8:1-4.
68. Lehtiö J., De Petris L. Lung cancer proteomics, clinical, and technological considerations. J. Proteomics 2010, 73:1851-1863.
69. Füzéry A.K., Levin J., Chan M.M., Chan D.W. Translation of proteomic biomarkers into FDA-approved cancer diagnostics: issues and challenges. Clin. Proteomics 2013, 10:13.
70. De Petris L., Orre L.M., Kanter L., Pernemalm M., Koyi H., Lewensohn R., Lehtiö J. Tumor expression of S100A6 correlates with survival of patients with stage I non-small-cell lung cancer. Lung Cancer 2009, 63:410-417.
71. Gharib T.G., Chen G., Wang H., Huang C.C., Prescott M.S., Shedden K., Misek D.E., Thomas D.G., Giordano T.J., Taylor J.M., Kardia S., Yee J., Orringer M.B., Hanash S., Beer D.G. Proteomic analysis of cytokeratin isoforms uncovers association with survival in lung adenocarcinoma. Neoplasia 2002, 4:440-448.
72. Li D.J., Deng G., Xiao Z.Q., Yao H.X., Li C., Peng F., Li M.Y., Zhang P.F., Chen Y.H., Chen Z.C. Identificating 14-3-3 sigma as a lymph node metastasis-related protein in human lung squamous carcinoma. Cancer Lett. 2009, 279:65-73.